<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00854061</url>
  </required_header>
  <id_info>
    <org_study_id>CL-PKT-0415083-P</org_study_id>
    <nct_id>NCT00854061</nct_id>
  </id_info>
  <brief_title>Study of T-PRED(TM) Compared to Pred Forte(R) II</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of T-PRED(TM) Compared to Pred Forte(R)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was a multi-center, randomized, double-masked, bioequivalence study. A total of&#xD;
      172 participants undergoing bilateral cataract surgery were assigned investigational product&#xD;
      to each eye according to a computer-generated randomization list for each of 2 study&#xD;
      variables: treatment with T-PRED or Pred Forte in the first eye undergoing cataract&#xD;
      extraction and the aqueous humor sampling time point.&#xD;
&#xD;
      The investigator determined which eye was clinically suited for the first operative&#xD;
      procedure; treatment of this eye was randomized to either T-PRED or Pred Forte. The second&#xD;
      eye received the other study treatment (RP if the first eye received T-PRED; T-PRED if the&#xD;
      first eye received Pred Forte) at the time of the second cataract extraction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Means Aqueous Humor Prednisolone Acetate Concentration</measure>
    <time_frame>35 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>T-Pred</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tobramycin prednisolone acetate combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pred Forte</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisolone acetate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T-Pred</intervention_name>
    <description>sterile ophthalmic solution</description>
    <arm_group_label>T-Pred</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pred Forte</intervention_name>
    <description>sterile ophthalmic solution</description>
    <arm_group_label>Pred Forte</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No active or adverse disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim McNamara, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>ISTA Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ISTA Pharmaceuticals, Inc.</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 26, 2009</study_first_submitted>
  <study_first_submitted_qc>February 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2009</study_first_posted>
  <results_first_submitted>August 18, 2020</results_first_submitted>
  <results_first_submitted_qc>October 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 20, 2020</results_first_posted>
  <disposition_first_submitted>September 2, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>September 2, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 12, 2011</disposition_first_posted>
  <last_update_submitted>October 16, 2020</last_update_submitted>
  <last_update_submitted_qc>October 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>Participants received both treatment groups, one in each eye.&#xD;
A total of 172 participants undergoing bilateral cataract surgery were assigned investigational product to each eye according to a computer-generated randomization list for each of 2 study variables: treatment with T-PRED or Pred Forte in the first eye undergoing cataract extraction and the aqueous humor sampling time point.&#xD;
The investigator determined which eye was clinically suited for the first operative procedure (surgery); treatment of this eye was randomized to either T-PRED or Pred Forte. The second eye received the other study treatment (RP if the first eye received T-PRED; T-PRED if the first eye received Pred Forte) at the time of the second cataract extraction.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="172"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 1st Surgery (T-PRED in One Eye and Pred Forte in the Other Eye)</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 2nd Surgery (T-PRED and Pred Forte in Opposite Eyes Compared to 1st Surgery)</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall</title>
          <description>Participants received both treatment groups, one in each eye. The treatment assigned to an eye (right or left) was randomly assigned.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="172"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.1" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Means Aqueous Humor Prednisolone Acetate Concentration</title>
        <time_frame>35 days</time_frame>
        <population>Participants received both treatment groups, one in each eye. The treatment assigned to an eye (right or left) was randomly assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>T-Pred</title>
            <description>Tobramycin prednisolone acetate combination&#xD;
T-Pred: sterile ophthalmic solution</description>
          </group>
          <group group_id="O2">
            <title>Pred Forte</title>
            <description>Prednisolone acetate&#xD;
Pred Forte: sterile ophthalmic solution</description>
          </group>
        </group_list>
        <measure>
          <title>Means Aqueous Humor Prednisolone Acetate Concentration</title>
          <population>Participants received both treatment groups, one in each eye. The treatment assigned to an eye (right or left) was randomly assigned.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.02" spread="9.61"/>
                    <measurement group_id="O2" value="131.65" spread="9.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>35 days</time_frame>
      <desc>The safety population was comprised of participants who received study treatment and had at least one post-baseline safety assessment. Participants received both treatment groups, one in each eye. The treatment assigned to an eye (right or left) was randomly assigned.g</desc>
      <group_list>
        <group group_id="E1">
          <title>T-Pred</title>
        </group>
        <group group_id="E2">
          <title>Pred-Forte</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 2.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>IOL dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Vitritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Contact sponsor directly for details.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Bausch Health</organization>
      <email>susan.harris@bauschhealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

